CD22-directed CAR T-cells

CD22-directed CAR T-cells are autologous or allogeneic T lymphocytes that have been genetically engineered to express a **chimeric antigen receptor (CAR)** targeting the **CD22 antigen**. CD22 is a sialoglycoprotein expressed primarily on the surface of B-cells, making it a promising target for immunotherapy in **B-cell malignancies** such as **acute lymphoblastic leukemia (B-ALL)** and **large B-cell lymphoma (LBCL)**, particularly in cases that are relapsed or refractory (R/R) and after loss of CD19 or failure of CD19-directed CAR T-cell therapies[1][2][4]. These therapies work by enabling T-cells to specifically recognize and kill CD22-expressing malignant B-cells. Multiple constructs exist (e.g., CAR22, CART22-65s), typically incorporating human or humanized anti-CD22 single-chain variable fragments (scFv) and costimulatory domains (such as 4-1BB). They have demonstrated high clinical remission rates in highly refractory B-ALL and LBCL, including after failure of prior CD19-targeted therapies, with generally manageable toxicity profiles[1][2][4][7].

Other names

CD22 CAR T-cellsCD-22 CAR T-cellsCD 22 CAR T-cellsCD22-targeted CAR T-cellsCD-22-targeted CAR T-cellsCD 22-targeted CAR T-cellsCAR22CAR-22CAR 22